Surgical Endoscopy

, Volume 30, Issue 9, pp 3802–3807 | Cite as

Significance of Nissen fundoplication after endoscopic radiofrequency ablation of Barrett’s esophagus

  • Ognjan SkrobićEmail author
  • Aleksandar Simić
  • Nebojša Radovanović
  • Nenad Ivanović
  • Marjan Micev
  • Predrag Peško



HALO radiofrequency ablation (RFA) has been proven as safe and efficient in eradication of both non- and dysplastic Barrett’s esophagus (BE). Definitive post-RFA treatment is yet to be determined.


RFA was performed in 56 patients with BE, 38 with intestinal metaplasia (IM) and 18 with low-grade dysplasia (LGD), and repeated in case of residual BE. Length of the BE was classified according to C&M criteria. Follow-up included regular upper GI endoscopies with biopsies 6 months, 1 and 2 years after the complete resolution of BE. Patients were divided into two groups regarding post-RFA treatment: those maintaining proton pump inhibitors (PPI) daily and those submitted to laparoscopic Nissen fundoplication (LNF) at least 3 months after BE eradication or synchronous with RFA.


There were no perforations or strictures related to RFA. Complete endoscopic resolution of BE was observed in 83.92 % patients (86.84 % IM and 77.77 % LGD), in 25 that maintained PPI and 22 in whom LNF was done. In PPI group, 2-year follow-up revealed BE recurrence in biopsy samples in 20 % of patients, while in LNF group 9.1 % of patients had recurrent IM. In overall sample of patients, no difference was noted regarding the influence of post-RFA treatment (p < 0.423). LNF proved superiority over PPI treatment in patients with long-segment BE (cutoff C > 4 cm, p < 0.021).


HALO RFA is a safe procedure, with high rate of success in complete eradication of BE in symptomatic GERD patients. LNF provides good protection for neosquamous epithelium and in selected group of patients could be offered as a first line of treatment after HALO RFA.


Barrett’s esophagus Radiofrequency ablation Laparoscopic Nissen fundoplication 


Compliance with ethical standards


Ognjan Skrobic, Aleksandar Simić, Nebojsa Radovanovic, Nenad Ivanovic, Marjan Micev and Predrag Pesko have no conflicts of interest or financial ties to disclose.


  1. 1.
    Spechler S, Souza R (2014) Barrett’s esophagus. N Engl J Med 371:836–845CrossRefPubMedGoogle Scholar
  2. 2.
    Thrift AP, Whiteman DC (2014) The incidence of esophageal adenocarcinoma continues to rise: analysis of period and birth cohort effects on recent trends. Ann Oncol 23:3155–3162CrossRefGoogle Scholar
  3. 3.
    Peters JH, Hagen JA, DeMeester SR (2004) Barrett’s esophagus. J Gastrointest Surg 8:1–17CrossRefPubMedGoogle Scholar
  4. 4.
    Wolfgarten E, Pütz B, Hölscher AH, Bollschweile E (2007) Duodeno-gastric-esophageal reflux—what is pathologic? Comparison of patients with Barrett’s esophagus and age-matched volunteers. J Gastrointest Surg 11:479–486CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Shaheen NJ, Sharma P, Overholt BF et al (2009) Radiofrequency ablation in Barrett’s esophagus with dysplasia. N Engl J Med 360:2277–2288CrossRefPubMedGoogle Scholar
  6. 6.
    Fleischer DE, Overholt BF, Sharma VK et al (2010) Endoscopic radiofrequency ablation for Barrett’s esophagus: 5-year outcomes from a prospective multicenter trial. Endoscopy 42:781–789CrossRefPubMedGoogle Scholar
  7. 7.
    Orman ES, Li N, Shaheen NJ (2013) Efficacy and durability of radiofrequency ablation for Barrett’s esophagus: systematic review and meta-analysis. Clin Gastroenterol Hepatol 11:1245–1255CrossRefPubMedGoogle Scholar
  8. 8.
    Krishnan K, Pandolfino J, Kahrilas P, Keefer L, Boris L, Komunduri S (2012) Increased risk for persistent intestinal metaplasia in patients with Barrett’s esophagus and uncontrolled reflux exposure before radiofrequency ablation. Gastroenterology 143:576–581CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Triadafilopulos G (2008) Proton pump inhibitors in Barrett’s esophagus: pluripotent but controversial. Eur Surg 40:58–65CrossRefGoogle Scholar
  10. 10.
    Frazzoni M, Savarino E, Manno M, Melotti G, Mirante VG, Mussetto A, Bertani H, Manta R, Conigliaro R (2009) Reflux patterns in patients with short-segment Barrett’s oesophagus: a study using impedance-pH monitoring off and on proton pump inhibitor therapy. Aliment Pharmacol Ther 30(5):508–515CrossRefPubMedGoogle Scholar
  11. 11.
    Korst RJ, Santana-Joseph S, Rutledge JR, Antler A, Bethala V, DeLillo A, Kutner D, Lee BE, Pazwash H, Pittman RH, Rahmin M, Rubinoff M (2011) Effect of hiatal hernia size and columnar segment length on the success of radiofrequency ablation for Barrett’s esophagus: a single-center, phase II clinical trial. J Thorac Cardiovasc Surg 142:1168–1173CrossRefPubMedGoogle Scholar
  12. 12.
    Gupta M, Iyer GP, Lutzke L, Gorospe EC, Abrams JA, Falk GW, Ginsberg GG, Rustgi AK, Lightdale CJ, Wang TC, Fudman DI, Poneros JM, Wang KK (2013) Recurrence of esophageal intestinal metaplasia after endoscopic mucosal resection and radiofrequency ablation of Barrett’s esophagus: results from a US multicenter consortium recurrence of Barrett’s esophagus after EMR and RFA. Gastroenterology 145:79–86CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Akiyama J, Marcus SN, Triadafilopoulos G (2012) Effective intra-esophageal acid control is associated with improved radiofrequency ablation outcomes in Barrett’s esophagus. Dig Dis Sci 57:2625–2632CrossRefPubMedGoogle Scholar
  14. 14.
    Jovov B, Shaheen NJ, Orlando GS, Djukic Z, Orlando RC (2013) Defective barrier function in neosquamous epithelium. Am J Gastroenterol. doi: 10.1038/ajg.2012.440 PubMedPubMedCentralGoogle Scholar
  15. 15.
    Raveli AM, Villanacci V, Ruzzenenti N, Grigolato P, Tobanelli P, Klersy C, Rindi G (2006) Dilated intercellular spaces: a major morphological feature of esophagitis. J Pediatr Gastroenterol Nutr 42:510–515CrossRefGoogle Scholar
  16. 16.
    Orlando RC (2014) How good is the neosquamous epithelium? Dig Dis 32:164–170CrossRefPubMedGoogle Scholar
  17. 17.
    O’Connell K, Velanovich V (2011) Effects of Nissen fundoplication on endoscopic endoluminal radiofrequency ablation of Barrett’s esophagus. Surg Endosc 25:830–834CrossRefPubMedGoogle Scholar
  18. 18.
    Johnson CS, Louie BE, Wille A, Dunst CM, Worrell SG, DeMeester SR, Reynolds J, Dixon J, Lipham JC, Lada M, Peters JH, Watson TJ, Farivar AS, Aye RW (2015) The durability of endoscopic therapy for treatment of Barrett’s metaplasia, dysplasia, and mucosal cancer after nissen fundoplication. J Gastrointest Surg 19:799–805CrossRefPubMedGoogle Scholar
  19. 19.
    Korst RJ, Santana-Joseph S, Rutledge JR, Antler A, Bethala V, DeLillo A, Kutner D, Lee BE, Pazwash H, Pittman RH, Rahmin M, Rubinoff M (2013) Patterns of recurrent and persistent intestinal metaplasia after successful radiofrequency ablation of Barrett’s esophagus. J Thorac Cardiovasc Surg 145:1529–1534CrossRefPubMedGoogle Scholar
  20. 20.
    Mashimo H (2013) Subsquamous intestinal metaplasia after ablation of Barrett’s esophagus: frequency and importance. Curr Opin Gastroenterol 29:454–459CrossRefPubMedGoogle Scholar
  21. 21.
    Phoa KN, Pouw RE, van Vilsteren FG, Sondermeijer CM, Ten Kate FJ, Visser M, Meijer SL, van Berge Henegouwen MI, Weusten BL, Schoon EJ, Mallant-Hent RC, Bergman JJ (2013) Remission of Barrett’s esophagus with early neoplasia 5 years after radiofrequency ablation with endoscopic resection: a Netherlands cohort study. Gastroenterology 145:96–104CrossRefPubMedGoogle Scholar
  22. 22.
    Vaccaro BJ, Gonzalez S, Poneros JM, Stevens PD, Capiak KM, Lightdale CJ, Abrams JA (2011) Detection of intestinal metaplasia after successful eradication of Barrett’s esophagus with radiofrequency ablation. Dig Dis Sci 56:1996–2000CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Goers TA, Leão P, Cassera MA, Dunst CM, Swanström LL (2011) Concomitant endoscopic radiofrequency ablation and laparoscopic reflux operative results in more effective and efficient treatment of Barrett’s esophagus. J Am Coll Surg 213:486–492CrossRefPubMedGoogle Scholar
  24. 24.
    Lenglinger J, Eisler M, Wrba F, Prager G, Zacherl J, Riegler M (2008) Update: histopathology-based definition of gastroesophageal reflux disease and Barrett’s esophagus. Eur Surg 40:165–175CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  • Ognjan Skrobić
    • 1
    Email author
  • Aleksandar Simić
    • 1
  • Nebojša Radovanović
    • 1
  • Nenad Ivanović
    • 1
  • Marjan Micev
    • 2
  • Predrag Peško
    • 1
  1. 1.Department of Esophageal Surgery, Clinical Center of Serbia, School of Medicine, First Surgical University HospitalUniversity of BelgradeBelgradeSerbia
  2. 2.Department of Digestive Pathology, Clinical Center of Serbia, School of Medicine, First Surgical University HospitalUniversity of BelgradeBelgradeSerbia

Personalised recommendations